Due to their prevalence, hallucinations are considered as one of the most frequent psychotic symptoms in Alzheimer's disease (AD). These psychotic manifestations reduce patients' well-being, increase the burden of caregivers, contribute to early institutionalization, and are related with the course of cognitive decline in AD. Considering their consequences, we provide a comprehensive account of the current state of knowledge about the prevalence and characteristics of hallucinations in AD. We propose a comprehensive and testable theoretical model about hallucinations in AD: the ALZHA (ALZheimer and HAllucinations) model. In this model, neurological, genetic, cognitive, affective, and iatrogenic factors associated with hallucinations in AD are highlighted. According to the ALZHA model, hallucinations in AD first involve trait markers (i.e., cognitive deficits, neurological deficits, genetic predisposition and/or sensory deficits) to which state markers that may trigger these experiences are added (e.g., psychological distress and/or iatrogenic factors). Finally, we provide recommendations for assessment and management of these psychotic manifestations in AD, with the aim to benefit patients, caregivers, and health professionals.
Introduction
Alzheimer's disease (AD) is a progressive neurodegenerative disease. Although the hallmark of AD is progressive episodic memory impairment, neuropsychiatric symptoms, especially hallucinations, are common in the disease. Hallucinations in AD reduce patients' well-being, increase the burden of caregivers, contribute to early institutionalization and, as we will depict later, are related with cognitive decline. Considering these consequences, we provide a comprehensive account of the current state of knowledge about hallucinations in AD. We first describe the prevalence, characteristics, and consequences of hallucinations in the disease, and then provide the currently proposed neurological, genetic, and cognitive and affective explanations. We then proceed to propose a new theoretical framework, which captures the complexity of underlying mechanisms of hallucinations in AD. This framework, named ALZHA (ALZheimer and Hallucinations), dissociates "state" and "trait" markers of hallucinations. Following current trends in research on hallucinations (Allen et al., 2008; Whalley et al., 2004) , state markers include psychological distress as well as iatrogenic factors associated with specific occurrences of hallucinations, while trait markers are risk factors for hallucinations, not directly linked with the presence/absence of the experience at the time of the assessment (i.e., difficulties in suppressing intrusive thoughts or memories, neurological deficits, genetic predisposition and/or sensory deficits). According to the ALZHA model, hallucinations in AD are mainly observed in patients who exhibit trait markers when one or more state markers are superimposed. Recommendations for assessment and management of hallucinations in AD close this review to provide useful guidelines for clinicians and caregivers.
The ALZHA model can be compared with existing models of hallucinations in other populations. In the Charles Bonnet syndrome, several theoretical models have proposed that lesions to specific neural substrates account for hallucinations (Burke, 2002; Pang, 2016) , not surprisingly as hallucinations in this syndrome are believed to be the consequence of disruption of the visual processing pathway. Prior research in the Charles Bonnet syndrome has demonstrated activation of visual cortical areas during visual hallucinations, of auditory and motor language areas during auditory-verbal hallucinations, and of somatosensory areas during somatic hallucinations. These findings suggest that, for hallucinations of a particular sensory modality in this syndrome, active involvement of the corresponding unimodal brain area is required (Ffytche, 2008) . Models on hallucinations in Parkinson's disease have also implicated specific neurological substrates (Diederich et al., 2009; Fenelon et al., 2006) , as well as discrepancies between conscious and non-conscious detection of stimuli (Lefebvre et al., 2016) . As for Schizophrenia, and psychosis in general, theoretical models have been reverse engineered based on neurotransmitter properties of antipsychotic medication (Patel et al., 2010) , implicated neural pathways (Kuhn and Gallinat, 2012) , cognitive mechanisms (Waters et al., 2012; Cho and Wu, 2013; Wilkinson, 2014) , or combinations of neurocognitive findings (Allen et al., 2008; Laroi et al., 2012; Aleman et al., 2003; Fovet et al., 2016; Waters et al., 2014; Allen et al., 2012) . Compared with these theoretical models, the ALZHA model proposes an integrative approach that productively combines well-characterized neurological, cognitive, affective, and iatrogenic features of the disease to show how they could result in hallucinations. A similar approach was adopted by computation models in schizophrenia (Fletcher and Frith, 2009; Looijestijn et al., 2015) . In our view, the ALZHA model offers a comprehensive view of a variety of factors that may contribute to hallucinations, which not only offers new theoretical advances, but also informs clinical approaches to reduce the destructive effects of hallucinations on the wellbeing of patients and caregivers.
Prevalence, characteristics, and consequences of hallucinations in AD
With a prevalence ranging from 4% to 76% (median 23%) (Bassiony and Lyketsos, 2003) , hallucinations are considered as one of the most frequent psychotic symptoms in AD (Scarmeas et al., 2005; Wilson et al., 2000; Ropacki and Jeste, 2005) . Hallucinations in AD are mainly visual and auditory (Jeste and Finkel, 2000; Tariot et al., 1995; Rubin et al., 1988) , but somatic, olfactory, and tactile experiences have also been reported (Burns et al., 1990; Deutsch et al., 1991) . Regardless of their sensory modality, hallucinations are associated with greater cognitive impairment and a more rapid deterioration (Scarmeas et al., 2005; Wilkosz et al., 2006; Weamer et al., 2009; Stern et al., 1987; Sweet et al., 2003) . Hallucinations have also been associated with an increase in mortality (Scarmeas et al., 2005) . In a relevant study, Wilson et al. (Wilson et al., 2005) assessed hallucinations and delusions in a group of 407 AD patients, monitoring the participants' vital status for a mean duration of 3.7 years. At study onset, hallucinations were present in 41.0% of participants, and during follow-up, 146 deaths occurred. Hallucinations were associated with a 78% increase in risk of death, and risk of death was more than double in those with both auditory and visual hallucinations. Interestingly, the same study (Wilson et al., 2005) did not find evidence of an association between delusions and mortality. Regarding the time of onset, hallucinations have been reported to occur at all stages of AD. A study observed hallucinations in 45 of 100 patients around the time of diagnosis (Jost and Grossberg, 1996) , while other studies reported that hallucinations manifest rarely in the early stages of AD (Bassiony and Lyketsos, 2003; Jost and Grossberg, 1996; Devanand et al., 1992) . Another study found that hallucinations in AD fluctuate with time but that their overall prevalence increases slowly with disease progression (Devanand et al., 1992) . In the last study, the authors reported that the recurrence rate for hallucinations was 95% in AD over one year (Levy et al., 1996) , suggesting that once these symptoms have occurred in the disease, they frequently re-appear.
On a behavioral level, hallucinations can have many consequences: for instance, they may be associated with verbal outbursts (Lerner et al., 1994) , aggressive behavior (Aarsland et al., 1996) , functional decline (Scarmeas et al., 2005; Haupt et al., 2000) , and falls (Bassiony et al., 2000) . A study has also reported an association between hallucinations and institutionalization in AD (Scarmeas et al., 2005) . Hallucinations are distressing for both AD patients and caregivers, as shown by studies demonstrating that neuropsychiatric symptoms in the disease are associated with higher rates of stress, depression, and high burden of care in caregivers (Ornstein et al., 2013; Rocca et al., 2010) . Taken together, hallucinations have several adverse consequences for patients and caregivers resulting in reduced quality of life, increased caregiver distress, and higher rates of admission to hospital and residential care facilities.
Neurological and genetic accounts for hallucinations in AD

Brain basis
Unlike the extensive body of research devoted to the exploration of the neural bases of hallucinations in schizophrenia (for review, see, (Allen et al., 2008; Waters et al., 2014; Aleman and Laroi, 2011; Jardri et al., 2013; Carter and Ffytche, 2015) ), only limited research has specifically addressed this question in AD (for a summary, see, Table 1 ). A study conducted in 812 AD patients found an association between hallucinations and reduced thickness in the lateral parietal cortex (Donovan et al., 2014) ; however, the study was based on data from the Neuropsychiatric Inventory brief questionnaire form (NPI-Q), and, as a result, the sensory modality of hallucinations was not assessed. The same issue was addressed by another study showing smaller occipital lobes in AD patients with visual hallucinations compared to those without (Holroyd et al., 2000) , inferring the role of pathological changes in modality-dependent cortices in these experiences. In a similar vein, a study demonstrated an association between visual hallucinations and increased occipital periventricular hyperintensities in AD (Lin et al., 2006) . Besides implicating the occipital cortex, hallucinations in AD were also found to involve frontotemporal and right parietal hypoperfusion (Lopez et al., 2001 ). More precisely, hallucinations in AD patients have been associated with lower regional perfusion of the right and left dorsolateral frontal, left ventral striatal, left anterior cingulate, left pulvinar and dorsolateral parietal cortex regions (Mega et al., 2000) . This prefrontal involvement may account for concomitant behaviours in AD (e.g., aggressive behavior). One study has reported an association between hallucinations in AD and the right anteriorposterior network, as well as with the anterior insula (Blanc et al., 2014) . More specifically, this study assessed hallucinations with the following questions "does the patient have hallucinations, or false visions, or voices? does he/she seem to hear or see things that are not present?". The study found associations between hallucinations and atrophy in the anterior part of the right insula, the left superior frontal gyrus, and the lingual gyri. Hallucinations were also associated with hypometabolism in the right ventral and dorsolateral prefrontal cortex, as well as with the right anterior part of the insula. In our view, there is a relative paucity of research on the specific neuroanatomical basis of hallucinations in AD. This paucity may be attributed to a greater interest in delusions in this disease (Reeves et al., 2012) , i.e., those erroneous beliefs that are firmly maintained by a patient despite contradictory evidence. Critically, the research on the neuroanatomical basis of hallucinations in AD has included small sample sizes, and has also mainly assessed hallucinations regarding their occurrence and modality, rather than their phenomenological characteristics (e.g., intensity, frequency, duration).
Genetic accounts
A relationship has been reported between hallucinations in AD and the apolipoprotein E (ApoE) 4 allele. The ApoE gene, located on chromosome 19, is the most important known genetic risk factor for sporadic AD (Saunders et al., 1993; El Haj et al., 2016a) . A study found a significant association between ApoE 4 and hallucinations in a large sample of 266 AD patients (Zdanys et al., 2007) . Although several later studies confirmed this finding, some studies did not replicate this association (for a review, see (DeMichele-Sweet and Sweet, 2010)), a discrepancy that may be due to differences in sample sizes and diagnostic criteria.
Cognitive and affective accounts for hallucinations in AD
Hallucinations, unsuppressed memories?
According to Hemsley (Hemsley, 2005) , inhibitory dysfunction lead to the emergence of redundant or irrelevant information from memory into awareness, generating hallucinations in Schizophrenia (for a similar view, see ). This model is supported by studies using the Inhibition of Currently Irrelevant Memories task. On this task, participants are typically instructed to forget previously exposed information (typically pictures) (Schnider and Ptak, 1999) . Using this task, Waters, Badcock (Waters et al., 2003) found difficulties in memory suppression in participants with schizophrenia, a difficulty that was significantly correlated with the severity of hallucinations. In the same vein, impairment in memory suppression, as observed on the Inhibition of Currently Irrelevant Memories task, was also considered responsible for intrusive thoughts in obsessive-compulsive disorder . Also, difficulties on this task were observed in undergraduate-students predisposed to hallucinations (Paulik et al., 2007) . Interestingly, the relationship between inhibitory mechanisms and hallucinations has also been observed in AD. A study found that hallucinations were mediated by inhibitory decline, as assessed with the Stroop task, in 31 patients with AD (El Haj et al., 2015a) . According to this study, hallucinations in AD patients may be related to difficulties in suppressing intrusive thoughts or memories.
The relationship between memory suppression and hallucinations was also assessed by studies using the directed forgetting task. In its conventional configuration, this task requires the processing of two lists of words (i.e., List 1 + List 2) (Bjork and Bjork, 1996) . Subjects are typically instructed to retain the words from List 1, after which they are asked either to continue remembering or to forget the words in it. Afterward, they are instructed to retain the words from List 2. Finally, in a recall test, they are asked to remember all the words from both lists, regardless of the intermediary "forget" or "remember" instructions. Typically, participants with the "forget" instruction tend to show poorer memory for the items in List 1 than the "remember" participants. This effect has been attributed to a suppressive effect of the "forget" instruction that reduces the accessibility to List 1 information (Geiselman et al., 1983 ). The directed forgetting task has been used to demonstrate relationships between deficits in memory suppression and hallucinations in schizophrenia. A study assessed the directed forgetting list task in schizophrenia participants with and without hallucinations and found that, relatively to those without hallucinations, participants with hallucinations presented inhibitory deficits on this task (i.e., they had difficulties suppressing the List 1 items) (Soriano et al., 2009 ). According to Soriano, Jimenez (Soriano et al., 2009) , difficulties in suppressing memory representations could underlie hallucinations in schizophrenia.
An important challenge for memory retrieval is the competition between appropriate and inappropriate information. This competition is normally reduced thanks to inhibitory control processes that suppress distractive memories, intrusive or unwanted thoughts, or interfering mental images (El Haj, 2016) . Hence, hallucinations in AD patients could be partly due to difficulties in suppressing memory representations, so that unwanted or repetitive thoughts intrude into consciousness. The relationship between inhibition and hallucinations can be further illustrated by a study in which AD patients had to remember whether they have had previously told or imagined telling facts to faces of famous people . Difficulties in the latter task were significantly correlated with performance on the Stroop task. Similarly, another study demonstrated significant correlations between compromise in source memory, i.e., the ability to remember the context in which information was acquired, and inhibition in AD (El Haj et al., 2012) . Interestingly, a study has used the directed forgetting task to demonstrate difficulties in suppressing personal memories in AD (El Haj et al., 2011) .
Taken together, these lines of evidence suggest that inhibitory dysfunction leads to the emergence of redundant or irrelevant information from long-term memory into awareness, generating hallucinations. This assumption can be supported by empirical studies showing that difficulties in intentionally inhibiting irrelevant thoughts or representations may be associated with hallucinations in Schizophrenia (Waters et al., 2006) , obsessivecompulsive disorder , as well as in individuals prone to hallucinations (Paulik et al., 2007; Soriano et al., 2009 ). More specifically, the memory suppression compromise model emphasizes both inhibitory decline and memory impairment in AD and fits with the model of Hemsley (Hemsley, 2005) who have proposed an interplay between inhibitory processing and memory impairment to account for the presence of hallucinations in schizophrenia (see also ). This model is of particular interest as the cardinal characteristic of AD is memory compromise (El Haj et al., 2015b) , therefore the inclusion of memory impairment in any model accounting for hallucinations aligns it with models that account for the broader cognitive and psychiatric phenomenology of the disease
Loneliness and depression
According to Fromm-Reichmann (Fromm-Reichmann, 1959) , loneliness makes people emotionally paralyzed and helpless, and may ultimately lead to the development of psychotic states. In a similar vein, extreme isolation in solitary confinement was reported to produce hallucinations in prisoners and hostages, perhaps, as a result of sensory deprivation (Launay and Slade, 1981) . In a study of 22 AD patients, we demonstrated significant correlations between hallucinations and loneliness as well as between hallucinations and social isolation (El Haj et al., 2016d) . This study argued that lonely AD patients generate internal stimuli to compensate for the lack of external stimulation and social contact and to fulfil their need to communicate. Hence, hallucinatory experiences may be regarded as a loophole allowing some AD patients, especially institutionalized ones, to escape the cycle of boredom, emptiness, and affective deprivation from social isolation. It is worth noting, however, that one study did not found a relationship between loneliness and hallucinations in patients with psychotic disorders (Badcock et al., 2015) , perhaps because the study captured only a crosssectional snap-shot of patients with psychosis without assessing longitudinal influences of loneliness on psychosis. Regarding AD, loneliness seems to play important role in hallucinations as, contrarily to other disorders, AD has a negative impact on functional abilities (e.g., walking, communicating), which limits social interactions and deprives patients of important social resources.
Independently of their relationship with loneliness and social isolation, hallucinations in AD were also found to be associated with depression (El Haj et al., 2015a) . Such a relationship mirrors the frequent occurrence of depressive disorders in individuals suffering from hallucinations (Birchwood and Chadwick, 1997) . Individuals with severe depression commonly report auditory hallucinations, which are generally transient and limited to single words or short phrases and, usually, communicating thoughts congruent with the patient's depressed mood (Chaudhury, 2010) . Since 25% to 70% of AD patients suffer from a comorbid depressive disorder (Bierman et al., 2009) , and both depression and hallucinations are important neuropsychiatric manifestations of AD (Bassiony and Lyketsos, 2003) , it is not surprising to observe a relationship between them. However, there is a need for studies to assess potential relationships between hallucinations and anxiety and poor emotion regulation in AD.
Assessment and management
Assessment
Due to the subjective nature of hallucinations, several challenges limit their assessment. Some AD patients with preserved insight may be reluctant to report their hallucinations to their families, in fear of negative consequences (e.g., their families may raise concerns about their mental health and/or begin to consider nursing home placement). On the other hand, anosognosia, i.e., the impaired ability to recognize the presence or appreciate the severity of cognitive deficits, may limit some patients' insight into the occurrence of hallucinations. Hence, assessment and management should engage patients as well as families and caregivers, in order to determine the hallucinations' modality, complexity, the time period for which the hallucinations have been present and the circumstances in which they occur. In a similar vein, it appears important to observe their occurrence in different settings, i.e., when she/he is alone or when interacting with other people.
Another issue to be considered in the assessment of hallucinations is the threshold beyond which hallucinations require psychological/medical care. Although hallucinations tend to be associated with psychotic disorders, some AD patients, especially those with mild stages of the disease, communicate with others about these manifestations, interpret or attribute significance or personal meaning to hallucinations ((e.g. "I probably see my (deceased) wife as I am missing her")) and overall manage to cope with them. The latter example illustrates the importance of considering the possibility of grieving when assessing hallucinations in AD. Since hallucinations may be associated, in some circumstances, with significant confusion and/or aggressive behaviors (Burghaus et al., 2012) , determining the threshold of care implies determining the short and long-term functional impairment or degree of danger for the patient and others.
An important tool that may be used to evaluate hallucinations in AD is the Launay-Slade Hallucination Scale (Launay and Slade, 1981) , an auto-evaluation scale that assesses a range of psychological factors and different hallucination modalities, as well as intrusive thoughts and vivid daydreams. Another tool is the Psycho-Sensory Hallucinations Scale (PSAS), a hetero-evaluation scale that includes four hallucination modalities (auditory, visual, olfactory/gustatory, and kinesthetic modalities) as well as the vivid sensation that somebody is present nearby (de Chazeron et al., 2015; Llorca et al., 2016) . Future research should incorporate these assessments because research on hallucinations in other clinical groups (e.g., schizophrenia) provide considerably more detail about the phenomenology of hallucinatory experience than research in AD. To overcome the effect of potential lack of insight of AD patients into the nature of hallucinatory experience (El Haj et al., 2016c) , especially those in advanced stages of the disease, research can compare auto-evaluation scales with hetero-evaluation ones. It is worth noting, however, that one priority is to validate these scales in AD, as, to the very best of our knowledge, no published study has validated any hallucinations scales in AD.
Management
Because hallucinations in AD are mainly visual and impaired visual acuity has been associated with visual hallucinations (Chapman et al., 1999) , the first step in their management should be visual acuity testing. Among various eye-diseases, visual hallucinations seem to be more persistent and more severe in AD patients with cataracts (Chapman et al., 1999) . Therefore, visual acuity testing and cataract treatment constitutes management priorities in the case of visual hallucinations. Auditory acuity testing should also be taken into account, as auditory hallucinations may also occur in AD, whereas increased risk of psychosis may exist in patients with hearing impairment (Linszen et al., 2016) . It is noteworthy, however, that in the advanced stages of AD, the benefit/risk ratio for surgery (e.g., cataract surgery) or general anesthesia can sway the decision against any intensive interventions.
General recommendations for coping with hallucinations in AD patients include environmental manipulation, such as turning off the radio or television to avoid any interference. Other environmental manipulations include removing mirrors and objects with complex shapes, avoiding any salient changes in the visual environment, and instructing patients to focus on the perceived object or shape more precisely, to approach or try to touch it or look at another direction or other object. Leaving a light on during nighttime can also be effective in reducing shadows, although lights should be adjusted to not disturb the patients' sleep. Because hallucinations tend to worsen under conditions of increased arousal, reducing arousal may also be effective. Sleep monitoring is also a worth consideration as research indicates that sleep dysfunction may contribute to psychotic symptoms in AD (Reeve et al., 2015) . Besides these general recommendations, appraisal strategies can be applied given that emotional reactions (e.g., depression and anxiety) to hallucinations are partially mediated by people's beliefs about the voice (Chadwick and Birchwood, 1995) . These beliefs include the identity (who is the voice/person?), purpose (why is the person talking to me and not someone else?), and degree of omnipotence (how powerful is the voice?). Appraisal of these beliefs can provide important insight into the hallucinatory phenomena. Acceptance and Commitment Therapy can also be recommended. This therapy encourages patients to accept and experience symptoms as mental events (i.e., mindfully) rather than judging their truthfulness and reacting to them. This therapy considers hallucinations to be similar to other private experiences (such as thoughts and memories) and directs focus on hallucinations when efforts to control, eliminate or avoid them lead to poor functioning (Gaudiano and Herbert, 2006) . This therapy may reduce aggressive behaviors or confusion, even though its effectiveness may be limited by the fact that severe hallucinations in dementia tend to occur in confused states with agitation (Burghaus et al., 2012) . Moreover, AD patients may benefit from Mindfulnessbased Cognitive Therapy to improve affective states and behavioral (Larouche et al., 2015) , but controlled trials are needed to determine the efficacy acceptance and commitment therapy in hallucinations.
Regarding pharmacological approaches, there are no antipsychotic agents specifically approved by the FDA for the treatment of hallucinations in AD (Burghaus et al., 2012) . Second-generation atypical antipsychotics are occasionally being prescribed by clinicians for treatment of psychotic symptoms at the request of the family (Burghaus et al., 2012; US Food, 2017) , although cardiac, metabolic, and cerebrovascular risks associated with these drugs have raised serious concerns (US Food, 2017) . The French National Authority for Health recommends non-pharmacological interventions as first-line treatments for behavioral disorders (Santé HAd, 2009 ). The French National Authority for Health also recommends that non-pharmacological approaches should substitute the use of medication in behavioral disorders. Treatment with a psychotropic agent can be prescribed when this first-line treatment is not sufficiently effective, such as in cases of refusal to cooperate, wandering, aggressive behavior, and especially, when hallucinations are severe enough to endanger the patient and/or others.
Overall, management of hallucinations in AD should always take into account their modality (e.g., auditory, visual), attempt to identify state markers, trait markers and contributing factors, and consider the individual subject's characteristics. Management should also take into account whether the target is a state or trait.
Summary: the ALZHA model
Due to their prevalence, hallucinations are considered as one of the most frequent psychotic symptoms in AD (Scarmeas et al., 2005; Wilson et al., 2000; Ropacki and Jeste, 2005) . These manifestations are also associated with cognitive and functional decline, disruptive behaviours, falls and early institutionalization in the disease. Despite their occurrence and their negative impact on the psychological and physiological health of patients and caregivers, relatively little research has been conducted on hallucinations in AD, in comparison with other neuropsychiatric and cognitive symptoms. This may be due to the fact that AD patients rarely mention their hallucinations, especially in the advanced stages of the disease, in which aphasia is prevalent. In this review, we attempted to highlight several cognitive and clinical accounts and integrate them into a coherent framework. Our review can be summarized in the ALZHA model (see Fig. 1 ), according to which hallucinations in AD are mainly observed in patients who exhibit trait markers, in whom subsequent state markers will induce hallucinations' occurrences. By proposing this model, we do not attribute hallucinations to any of the reviewed factors in isolation (e.g., psychological distress, iatrogenic factors, memory suppression, neurological deficit, sensory deficits) but rather to the complex interaction between these factors. This consideration is important as, in light of the reviewed literature, it is very difficult to identify any single factor as a main contributor to hallucinations in AD. Generally speaking, this position fits with the general view that considers AD as a clinical syndrome that encompasses a spectrum of cognitive, psychiatric and neurological manifestations with variable presence of senile plaques and neurofibrillary tangles at different brain areas partly accounting for the phenotypic variability (Dubois et al., 2010) .
Compared with other models on hallucinations, our model has the merit to incorporate a wide variety of neurological, cognitive, affective, and iatrogenic factors that can be involved in hallucinations. Another originality of the ALZHA model is the distinction between traits (i.e., cognitive deficits, neurological deficits, genetic predisposition and/or sensory deficits) that may predispose patients to hallucinations and states that may trigger these experiences. In our view, this distinction may explain why these experiences may occur in some AD patients but not in others, as According to the ALZHA model, hallucinatory experiences in Alzheimer's disease mainly occur in patients with trait markers (i.e., difficulties in suppressing intrusive thoughts or memories, neurological deficits, genetic predisposition and/or sensory deficits), who experience, at a given moment, one or more state markers that will trigger the experience (e.g., psychological distress and/or iatrogenic factors)..
well as why such experiences may occur only at given times during AD progression
Conclusion and future directions
Research studies in AD have so far addressed isolated aspects of hallucinations (e.g., focusing on their neurological, cognitive or affective dimension). As suggested by the ALZHA model, we believe that future research should consider the multiplicity of mechanisms contributing to hallucinations in AD, but also the interactions between these mechanisms and carefully differentiate between state and trait mechanisms. Regarding cognitive mechanisms, we proposed the suppression hypothesis, but we also believe that more empirical research is needed regarding the potential relationship between hallucinations and source monitoring. The relationship between hallucinations and source monitoring has been extensively studied in schizophrenia, it would be of great interest to test this association in AD, especially in the light of research suggesting impaired source monitoring in AD (El Haj and Kessels, 2013; El Haj et al., 2016b) . In a similar vein, there is a lack of research on the relationship between hallucinations and visual perception in AD. Future research should assess whether visual hallucinations in AD involve the ventral 'what' and/or dorsal 'where' visual processing pathways, which support object recognition and spatial location, respectively. Several hypotheses can be tested, e.g., whether visual hallucinations in AD may reflect compromise in the ability to process visual stimuli, to integrate sensory information and prior expectations, and/or to generate correct interpretations of visual input. Finally, further research is also required to compare hallucinations in AD with those in other dementias (e.g. Lewy body dementia). This comparison could pave the way for testing the specificities of hallucination in AD and identify potential links with neuropathological hallmarks (e.g., the accumulation of amyloidbeta (A␤) plaques or tau tangles).
